Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
Despite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed to evaluate the reproducibility of the safety and efficacy of commercial...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.740079/full |
id |
doaj-e505e90b69714fdf86208ecf0841bd1a |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Massimo Martino Annalisa Pitino Mercedes Gori Benedetto Bruno Benedetto Bruno Alessandra Crescimanno Vincenzo Federico Alessandra Picardi Alessandra Picardi Stefania Tringali Claudia Ingrosso Paola Carluccio Domenico Pastore Gerardo Musuraca Annalisa Paviglianiti Adriana Vacca Bianca Serio Gabriella Storti Nicola Mordini Salvatore Leotta Michele Cimminiello Lucia Prezioso Barbara Loteta Anna Ferreri Fabrizia Colasante Emanuela Merla Luisa Giaccone Luisa Giaccone Alessandro Busca Maurizio Musso Renato Scalone Nicola Di Renzo Serena Marotta Patrizio Mazza Pellegrino Musto Immacolata Attolico Carmine Selleri Filippo Antonio Canale Marta Pugliese Giovanni Tripepi Gaetana Porto Giovanni Martinelli Angelo Michele Carella Claudio Cerchione |
spellingShingle |
Massimo Martino Annalisa Pitino Mercedes Gori Benedetto Bruno Benedetto Bruno Alessandra Crescimanno Vincenzo Federico Alessandra Picardi Alessandra Picardi Stefania Tringali Claudia Ingrosso Paola Carluccio Domenico Pastore Gerardo Musuraca Annalisa Paviglianiti Adriana Vacca Bianca Serio Gabriella Storti Nicola Mordini Salvatore Leotta Michele Cimminiello Lucia Prezioso Barbara Loteta Anna Ferreri Fabrizia Colasante Emanuela Merla Luisa Giaccone Luisa Giaccone Alessandro Busca Maurizio Musso Renato Scalone Nicola Di Renzo Serena Marotta Patrizio Mazza Pellegrino Musto Immacolata Attolico Carmine Selleri Filippo Antonio Canale Marta Pugliese Giovanni Tripepi Gaetana Porto Giovanni Martinelli Angelo Michele Carella Claudio Cerchione Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience Frontiers in Oncology cytomegalovirus infection allogeneic stem cell transplantation prophylaxis real-world data Letermovir |
author_facet |
Massimo Martino Annalisa Pitino Mercedes Gori Benedetto Bruno Benedetto Bruno Alessandra Crescimanno Vincenzo Federico Alessandra Picardi Alessandra Picardi Stefania Tringali Claudia Ingrosso Paola Carluccio Domenico Pastore Gerardo Musuraca Annalisa Paviglianiti Adriana Vacca Bianca Serio Gabriella Storti Nicola Mordini Salvatore Leotta Michele Cimminiello Lucia Prezioso Barbara Loteta Anna Ferreri Fabrizia Colasante Emanuela Merla Luisa Giaccone Luisa Giaccone Alessandro Busca Maurizio Musso Renato Scalone Nicola Di Renzo Serena Marotta Patrizio Mazza Pellegrino Musto Immacolata Attolico Carmine Selleri Filippo Antonio Canale Marta Pugliese Giovanni Tripepi Gaetana Porto Giovanni Martinelli Angelo Michele Carella Claudio Cerchione |
author_sort |
Massimo Martino |
title |
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience |
title_short |
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience |
title_full |
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience |
title_fullStr |
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience |
title_full_unstemmed |
Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience |
title_sort |
letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
Despite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed to evaluate the reproducibility of the safety and efficacy of commercially available letermovir for CMV prophylaxis in a real-world setting. Endpoints were rates of clinically significant CMV infection (CSCI), defined as CMV disease or CMV viremia reactivation within day +100-+168. 204 adult CMV-seropositive allo-SCT recipients from 17 Italian centres (median age 52 years) were treated with LET 240 mg/day between day 0 and day +28. Overall, 28.9% of patients underwent a haploidentical, 32.4% a matched related, and 27.5% a matched unrelated donor (MUD) transplant. 65.7% were considered at high risk of CSCI and 65.2% had a CMV seropositive donor. Low to mild severe adverse events were observed in 40.7% of patients during treatment [gastrointestinal toxicity (36.3%) and skin rash (10.3%)]. Cumulative incidence of CSCI at day +100 and day +168 was 5.4% and 18.1%, respectively, whereas the Kaplan-Meier event rate was 5.8% (95% CI: 2.4-9.1) and 23.3% (95% CI: 16.3-29.7), respectively. Overall mortality was 6.4% at day +100 and 7.3% at day +168. This real-world experience confirms the efficacy and safety of CMV. |
topic |
cytomegalovirus infection allogeneic stem cell transplantation prophylaxis real-world data Letermovir |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.740079/full |
work_keys_str_mv |
AT massimomartino letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT annalisapitino letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT mercedesgori letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT benedettobruno letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT benedettobruno letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT alessandracrescimanno letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT vincenzofederico letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT alessandrapicardi letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT alessandrapicardi letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT stefaniatringali letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT claudiaingrosso letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT paolacarluccio letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT domenicopastore letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT gerardomusuraca letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT annalisapaviglianiti letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT adrianavacca letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT biancaserio letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT gabriellastorti letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT nicolamordini letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT salvatoreleotta letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT michelecimminiello letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT luciaprezioso letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT barbaraloteta letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT annaferreri letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT fabriziacolasante letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT emanuelamerla letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT luisagiaccone letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT luisagiaccone letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT alessandrobusca letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT mauriziomusso letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT renatoscalone letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT nicoladirenzo letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT serenamarotta letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT patriziomazza letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT pellegrinomusto letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT immacolataattolico letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT carmineselleri letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT filippoantoniocanale letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT martapugliese letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT giovannitripepi letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT gaetanaporto letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT giovannimartinelli letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT angelomichelecarella letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience AT claudiocerchione letermovirprophylaxisforcytomegalovirusinfectioninallogeneicstemcelltransplantationarealworldexperience |
_version_ |
1717374552400461824 |
spelling |
doaj-e505e90b69714fdf86208ecf0841bd1a2021-09-20T12:34:55ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.740079740079Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World ExperienceMassimo Martino0Annalisa Pitino1Mercedes Gori2Benedetto Bruno3Benedetto Bruno4Alessandra Crescimanno5Vincenzo Federico6Alessandra Picardi7Alessandra Picardi8Stefania Tringali9Claudia Ingrosso10Paola Carluccio11Domenico Pastore12Gerardo Musuraca13Annalisa Paviglianiti14Adriana Vacca15Bianca Serio16Gabriella Storti17Nicola Mordini18Salvatore Leotta19Michele Cimminiello20Lucia Prezioso21Barbara Loteta22Anna Ferreri23Fabrizia Colasante24Emanuela Merla25Luisa Giaccone26Luisa Giaccone27Alessandro Busca28Maurizio Musso29Renato Scalone30Nicola Di Renzo31Serena Marotta32Patrizio Mazza33Pellegrino Musto34Immacolata Attolico35Carmine Selleri36Filippo Antonio Canale37Marta Pugliese38Giovanni Tripepi39Gaetana Porto40Giovanni Martinelli41Angelo Michele Carella42Claudio Cerchione43Centro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, ItalyIstituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (CNR), Roma, ItalyIstituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (CNR), Roma, ItalyDipartimento di Oncologia, SSD Trapianto Allogenico di Cellule Staminali, AOU Città della Salute e della Scienza di Torino, Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute, Divisione di Ematologia, Università di Torino, Torino, ItalyUnità Operativa di Oncoematologia e TMO, Istituto “La Maddalena”, Palermo, ItalyEmatologia e Trapianto di Cellule Staminali, Polo Ospedaliero “Vito Fazzi”, Lecce, ItalyUOC Ematologia con Trapianto CSE, AORN “Antonio Cardarelli”, Napoli, ItalyDipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, Roma, ItalyUOSD UTMO, AOR Villa “Sofia Cervello”, Palermo, Italy0Ematologia e Trapianto di Midollo Osseo, Ospedale “San Giuseppe Moscati”, Taranto, Italy1UOC di Ematologia con Trapianto, Dipartimento di Emergenza e Trapianti d’Organo, Università degli Studi “Aldo Moro” e AOUC Policlinico di Bari, Bari, Italy2Divisione di Ematologia, Ospedale “Antonio Perrino”, Brindisi, Italy3Unità di Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy4UO Ematologia - CTMO, Polo Ospedaliero “Armando Businco”, Cagliari, Italy5Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Salerno, Salerno, Italy6Unità di Ematologia, Azienda Ospedaliera “San Giuseppe Moscati”, Avellino, Italy7SC Ematologia, Azienda Ospedaliera “S. Croce e Carle”, Cuneo, Italy8Programma di Trapianto Emopoietico, Azienda Policlinico “Vittorio Emanuele”, Catania, Italy9Divisione Universitaria di Ematologia, Ospedale “San Carlo”, Potenza, Italy0Ematologia e Centro Trapianti Midollo Osseo (CTMO), Dipartimento ad Attività Integrata Medicina Generale e Specialistica, Azienda Ospedaliero-Universitaria di Parma, Parma, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy1Ospedale I.R.C.C.S. Casa Sollievo della Sofferenza - Centro Trapianti di Cellule Staminali, San Giovanni Rotondo, Italy1Ospedale I.R.C.C.S. Casa Sollievo della Sofferenza - Centro Trapianti di Cellule Staminali, San Giovanni Rotondo, ItalyDipartimento di Oncologia, SSD Trapianto Allogenico di Cellule Staminali, AOU Città della Salute e della Scienza di Torino, Torino, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute, Divisione di Ematologia, Università di Torino, Torino, ItalyDipartimento di Oncologia, SSD Trapianto Allogenico di Cellule Staminali, AOU Città della Salute e della Scienza di Torino, Torino, ItalyUnità Operativa di Oncoematologia e TMO, Istituto “La Maddalena”, Palermo, ItalyUnità Operativa di Oncoematologia e TMO, Istituto “La Maddalena”, Palermo, ItalyEmatologia e Trapianto di Cellule Staminali, Polo Ospedaliero “Vito Fazzi”, Lecce, ItalyUOC Ematologia con Trapianto CSE, AORN “Antonio Cardarelli”, Napoli, Italy0Ematologia e Trapianto di Midollo Osseo, Ospedale “San Giuseppe Moscati”, Taranto, Italy1UOC di Ematologia con Trapianto, Dipartimento di Emergenza e Trapianti d’Organo, Università degli Studi “Aldo Moro” e AOUC Policlinico di Bari, Bari, Italy1UOC di Ematologia con Trapianto, Dipartimento di Emergenza e Trapianti d’Organo, Università degli Studi “Aldo Moro” e AOUC Policlinico di Bari, Bari, Italy5Dipartimento di Medicina, Chirurgia e Odontoiatria, Università di Salerno, Salerno, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy2Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (CNR), Reggio Calabria, ItalyCentro Unico Regionale Trapianti Cellule Staminali e Terapie Cellulari (CTMO), Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy3Unità di Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy1Ospedale I.R.C.C.S. Casa Sollievo della Sofferenza - Centro Trapianti di Cellule Staminali, San Giovanni Rotondo, Italy3Unità di Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyDespite effective treatments, cytomegalovirus (CMV) continues to have a significant impact on morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients. This multicenter, retrospective, cohort study aimed to evaluate the reproducibility of the safety and efficacy of commercially available letermovir for CMV prophylaxis in a real-world setting. Endpoints were rates of clinically significant CMV infection (CSCI), defined as CMV disease or CMV viremia reactivation within day +100-+168. 204 adult CMV-seropositive allo-SCT recipients from 17 Italian centres (median age 52 years) were treated with LET 240 mg/day between day 0 and day +28. Overall, 28.9% of patients underwent a haploidentical, 32.4% a matched related, and 27.5% a matched unrelated donor (MUD) transplant. 65.7% were considered at high risk of CSCI and 65.2% had a CMV seropositive donor. Low to mild severe adverse events were observed in 40.7% of patients during treatment [gastrointestinal toxicity (36.3%) and skin rash (10.3%)]. Cumulative incidence of CSCI at day +100 and day +168 was 5.4% and 18.1%, respectively, whereas the Kaplan-Meier event rate was 5.8% (95% CI: 2.4-9.1) and 23.3% (95% CI: 16.3-29.7), respectively. Overall mortality was 6.4% at day +100 and 7.3% at day +168. This real-world experience confirms the efficacy and safety of CMV.https://www.frontiersin.org/articles/10.3389/fonc.2021.740079/fullcytomegalovirus infectionallogeneic stem cell transplantationprophylaxisreal-world dataLetermovir |